Skip to content
Back to meeting Original
Aakash Desai· @ADesaiMD · X·· 17 hours agoScore70

KRASCENDO

Body

Krascendo 1 #ESMO26: divarasib vs sotorasib/adagrasib, pretreated KRAS G12C NSCLC
➡️ mPFS 9.8 vs 5.7 mo, HR 0.58
➡️ mOS 17.7 vs 12.0 mo, HR 0.56
➡️ ORR 58 vs 32%
➡️ G3-4 TRAEs 24.6 vs 34.5%; diarrhea 66 vs 38%
Where does first-gen G12C fit?

@LungCancerRx @OncoAlert @oncodaily

18 views · 1 like · 1 repost · 0 replies

Conference abstracts

Source: Aakash Desai · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.